The present invention relates to a method of treating cancer in a human, wherein cancer is multiple myeloma, and to a pharmaceutical combination of bortezomib and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide in the form of a monohydrochloride salt suitable for such treatment. In particular, the invention relates to a method of treating cancer, wherein cancer is multiple myeloma, the method comprising administering bortezomib and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, wherein the combination compounds are administered consecutively. The invention also relates to a kit comprising said combination and to the use of said combination for the preparation of a medicament for treating multiple myeloma.
